COMMERCE PATENT AND TRADEMARK OFFICE

O THE UNITED STATES TRANSMITTAL LETTE DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATIONNO. (IF KNOWN, SEE 37 CFR

INTERNATIONALAPPLICATIONNO.
PCT/US98/07587

INTERNATIONAL FILING DATE
16 April 1998

PRIORITY DATE CLAIMED

18 April 1997

TITLE OF INVENTION	
Type II TGF-Beta Receptor/Immuno	globulin Constant Region Fusion Proteins

	als,	et al.
Appli	cant h	erewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:
1.	×	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2.		This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4.		A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date
5.	×	A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
		a. \square is transmitted herewith (required only if not transmitted by the International Bureau).
ī.		b. \square has been transmitted by the International Bureau.
 H		c. 🛛 is not required, as the application was filed in the United States Receiving Office (RO/US).
÷ 6.		A translation of the International Application into English (35 U.S.C. 371(c)(2)).
		A copy of the International Search Report (PCT/ISA/210).
∦ 8.		Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
garaj _a		a. are transmitted herewith (required only if not transmitted by the International Bureau).
Ě		b. have been transmitted by the International Bureau.
7		c. \square have not been made; however, the time limit for making such amendments has NOT expired.
		d. have not been made and will not be made.
9.		A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
<u></u> 10.		An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11.		A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12.		A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
I	tems :	13 to 18 below concern document(s) or information included:
13.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15.		A FIRST preliminary amendment.
l		A SECOND or SUBSEQUENT preliminary amendment.
16.		A substitute specification.
17.		A change of power of attorney and/or address letter.
18.	\boxtimes	Certificate of Mailing by Express Mail
19.		Other items or information:

INTERNATIONAL APPLICATIONNO. APPLICATIONNO A018 PCT/US98/07587 CALCULATIONS PTO USE ONLY The following fees are submitted:. 20. BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : \$930.00 ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) \$720.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) \$790.00 but international search fee paid to USPTO (37 CFR 1.445(a)(2)) . . Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2) paid to USPTO \$1,070.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$98.00 ENTER APPROPRIATE BASIC FEE AMOUNT = \$930.00 □ 30 Surcharge of \$130.00 for furnishing the oath or declaration later than \$0.00 months from the earliest claimed priority date (37 CFR 1.492 (e)). RATE NUMBER EXTRA NUMBER FILED \$22.00 \$22.00 - 20 = Total claims \$410.00 \$82.00 - 3= ndependent claims \$0.00 Multiple Dependent Claims (check if applicable) \$1,362.00 TOTAL OF ABOVE CALCULATIONS = Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). \Box \$0.00 \$1,362.00 SUBTOTAL □ 30 Processing fee of \$130.00 for furnishing the English translation later than □ 20 \$0.00 nonths from the earliest claimed priority date (37 CFR 1.492 (f)). \$1,362.00 TOTAL NATIONAL FEE = Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). \$0.00 \$1,362.00 TOTAL FEES ENCLOSED Amount to be: refunded \$ charged to cover the above fees is enclosed. A check in the amount of to cover the above fees. in the amount of \$1,362.00 Please charge my Deposit Account No. 02-2327 X A duplicate copy of this sheet is enclosed. The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment A duplicate copy of this sheet is enclosed. 02-2327 to Deposit Account No. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status. SEND ALL CORRESPONDENCE TO: SIGNATURE Warren A. Kaplan, BIOGEN, INC. Warren A. Kaplan 14 Cambridge Center Cambridge, MA 02142 NAME (617) 679-3598 34,199 REGISTRATION NUMBER DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE THE PATENT COOPERATION TREATY

In re application of:

Gotwals, et al.

International Serial No.:

PCT/US98/07587

Filing Date:

April 16, 1998

For:

12

Type II TGF-Beta Receptor/Immunoglobulin Constant Region

Fusion Proteins

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Post Office as Express Label No. EL272416480US in an Express Mail Envelope addressed to BOX PCT, Assistant Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: Ochber 28, 1999 Signature:

Transmittal Letter

Enclosed please find a Petition for Revival of An International Application For Patent Designating the U.S. Abandoned Unintentionally Under 37 CFR 1.137(b), Transmittal Letter to the United States Designated/Elected Office Concerning a Filing Under 35 U.S.C. 371, and a copy of the published PCT application under Express Mail Label Number EL272416476US.

The Commissioner is hereby authorized to charge our deposit account No. 02-2327 to cover the above fees including fees for Petition and National filing including excess claims. The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment to Deposit Account No. 02-2327.

Respectfully submitted,

Want/w

io/\2/99
Date: ____

Warren A. Kaplan Reg. No. 34,199

BIOGEN, INC.

14 Cambridge Center Cambridge, MA 02142

(617) 679-3598